These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8568125)

  • 1. Desensitization treatment for anaphylactoid reactions to desferrioxamine in a pediatric patient with thalassemia.
    La Rosa M; Romeo MA; Di Gregorio F; Russo G
    J Allergy Clin Immunol; 1996 Jan; 97(1 Pt 1):127-8. PubMed ID: 8568125
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful desensitization of a child with desferrioxamine hypersensitivity.
    Patriarca G; Schiavino D; Nucera E; Pellegrino S; Valle D; Della Corte AM; Pagliari G
    J Investig Allergol Clin Immunol; 1995; 5(5):294-5. PubMed ID: 8574439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful desensitization of a case with desferrioxamine hypersensitivity.
    Gülen F; Demir E; Tanaç R; Aydinok Y; Gulen H; Yenigün A; Can D
    Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine.
    Surapolchai P; Poachanukoon O; Satayasai W; Silapamongkonkul P
    J Med Assoc Thai; 2014 Aug; 97 Suppl 8():S217-22. PubMed ID: 25518318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid desensitisation for desferrioxamine anaphylactic reaction.
    Miller KB; Rosenwasser LJ; Bessette JA; Beer DJ; Rocklin RE
    Lancet; 1981 May; 1(8228):1059. PubMed ID: 6112440
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
    Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
    Minerva Pediatr; 2000 Apr; 52(4):235-41. PubMed ID: 11995208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary embolism and intravenous high-dose desferrioxamine.
    Cianciulli P
    Haematologica; 1992; 77(4):368-9. PubMed ID: 1427452
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid desensitisation for desferrioxamine anaphylactoid reaction.
    Bousquet J; Navarro M; Robert G; Aye P; Michel FB
    Lancet; 1983 Oct; 2(8354):859-60. PubMed ID: 6137689
    [No Abstract]   [Full Text] [Related]  

  • 9. [Rapid desensitization for anaphylactoid reactions to desferrioxamine].
    Di Marco JN; Poujol A; Rimet Y; Fardeau MF; Brusquet Y; Poirier R
    Arch Pediatr; 1994 Oct; 1(10):959. PubMed ID: 7842079
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of iron chelator desferrioxamine on serum zinc levels in patients with beta thalassemia major.
    Sultan S; Irfan SM; Kakar J; Zeeshan R
    Malays J Pathol; 2015 Apr; 37(1):35-8. PubMed ID: 25890611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and management of pediatric patients with anaphylactoid reactions to deferoxamine mesylate.
    Somech R; Seaban-Adel K; Atkinson A; Kirby-Allen M
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):575-6. PubMed ID: 18219844
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine.
    Rego EM; Neto EB; Simões BP; Zago MA
    Am J Hematol; 1998 Aug; 58(4):340-1. PubMed ID: 9692403
    [No Abstract]   [Full Text] [Related]  

  • 13. Allergy to desferrioxamine.
    Romeo MA; Di Gregorio F; Schiliro G
    J Inherit Metab Dis; 1984; 7(3):121. PubMed ID: 6438394
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
    Athanassiou-Metaxa M; Kousi A; Hatzipantelis ES; Tsatra I; Ikonomou M; Perifanis V; Tsantali H
    Haematologica; 2004 Apr; 89(4):ELT07. PubMed ID: 15075120
    [No Abstract]   [Full Text] [Related]  

  • 15. Management and successful desensitization in methotrexate-induced anaphylaxis.
    Bouchireb K; Dodille A; Ponvert C; Gouraud F; Dubrel M; Brugières L
    Pediatr Blood Cancer; 2009 Feb; 52(2):295-7. PubMed ID: 18855892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
    Songdej D; Sirachainan N; Wongwerawattanakoon P; Sasanakul W; Kadegasem P; Sungkarat W; Chuansumrit A
    Acta Haematol; 2015; 133(2):226-36. PubMed ID: 25376266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular involvement correlated with age in patients affected by major and intermedia beta-thalassemia treated or not with desferrioxamine.
    Rinaldi M; Della Corte M; Ruocco V; D'Onofrio C; Zanotta G; Romano A
    Metab Pediatr Syst Ophthalmol (1985); 1993; 16(1-2):23-5. PubMed ID: 8259071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major.
    Davies GI; Davies D; Charles S; Barnes SL; Bowden D
    Pediatr Allergy Immunol; 2017 Mar; 28(2):199-201. PubMed ID: 27797415
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases.
    Vaskaridou E; Konstantopoulos K; Kyriakou D; Loukopoulos D
    Haematologica; 1993; 78(3):183-4. PubMed ID: 8375749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.